Recent News

• 05.27.2025 - Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Viru
• 05.27.2025 - Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Viru
• 05.23.2025 - Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
• 05.23.2025 - Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
• 05.21.2025 - Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
• 05.21.2025 - Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference
• 05.15.2025 - Q1 2025 Invivyd Earnings Conference Call
• 05.15.2025 - Q1 2025 Invivyd Earnings Conference Call

Recent Filings

• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.20.2025 - 8-K Current report
• 05.15.2025 - EX-99.1 EX-99.1